Esketamine nasal spray offers rapid improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update September 1, 2019 DOI: 10.1002/pu.30468 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Interventions | Esketamine nasal spray antidepressant |
| Topics | Depression Esketamine |
| Key points | Esketamine nasal spray plus a newly initiated antidepressant was reported to be more effective than a new antidepressant plus placebo at reducing depressive symptoms in patients with treatment-resistant depression, according to a Phase 3 study. |
Abstract
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for treatment‐resistant depression in adults. Study results were published online May 21 in the American Journal of Psychiatry.